Showing results (91-100 of 162) with videos related to

Sort By:
Pageof 17
Scientific Reports|September 2, 2017
LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cellsSo-Young Lim, Iris Macheleidt, Priya Dalvi, et al.
Scientific Reports|November 2, 2018
Author Correction: LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cellsSo-Young Lim, Iris Macheleidt, Priya Dalvi, et al.
NPJ Precision Oncology|June 7, 2018
<i>ALK</i><sup>G1269A</sup> mutation as a potential mechanism of acquired resistance to crizotinib in an <i>ALK</i>-rearranged inflammatory myofibroblastic tumorSebastian Y F Michels, Andreas H Scheel, Thomas Wündisch, et al.
Der Pathologe|May 27, 2021
[MSI testing : What is new? What should be considered? German version]Josef Rüschoff, Gustavo Baretton, Hendrik Bläker, et al.
The American Journal of Surgical Pathology|January 19, 2012
Optimal lymph node harvest in rectal cancer (UICC stages II and III) after preoperative 5-FU-based radiochemotherapy. Acetone compression is a new and highly efficient methodAnastasia Gehoff, Oliver Basten, Thilo Sprenger, et al.
The Journal of Pathology|June 10, 2018
Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutationsChristina Alidousty, Till Baar, Luciano G Martelotto, et al.
Der Pathologe|September 3, 2021
MSI testing : What's new? What should be considered?Josef Rüschoff, Gustavo Baretton, Hendrik Bläker, et al.
Virchows Archiv : an International Journal of Pathology|March 23, 2016
NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trialVolker Endris, Albrecht Stenzinger, Nicole Pfarr, et al.
International Journal of Cancer|September 5, 2015
NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomasLydia Meder, Katharina König, Luka Ozretić, et al.
Virchows Archiv : an International Journal of Pathology|November 11, 2022
Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissueClaudia Vollbrecht, Inga Hoffmann, Annika Lehmann, et al.
Pageof 17